American Society of Hematology

Fig. 1.

$Fig. 1. CDDO induction of apoptosis of fludarabine-refractory CLL patient samples. / CLL B cells from patients with a new diagnosis of fludarabine-A sensitivity (F-Ara-A sensitive) (n = 5) (panel B), from F-Ara-A–resistant patients (n = 8) (panel A), or normal B cells isolated from tonsil (n = 2) (panel C) were cultured in the presence or absence of F-Ara-A (0.1/1.0 μM) or CDDO (0.1/0.5/1.0 μM). CLL B cells were recovered from cultures, and the percentage of apoptosis was determined by annexin V–FITC/PI double staining with the use of flow cytometry analysis (data represent means ± SE).$

CDDO induction of apoptosis of fludarabine-refractory CLL patient samples.

CLL B cells from patients with a new diagnosis of fludarabine-A sensitivity (F-Ara-A sensitive) (n = 5) (panel B), from F-Ara-A–resistant patients (n = 8) (panel A), or normal B cells isolated from tonsil (n = 2) (panel C) were cultured in the presence or absence of F-Ara-A (0.1/1.0 μM) or CDDO (0.1/0.5/1.0 μM). CLL B cells were recovered from cultures, and the percentage of apoptosis was determined by annexin V–FITC/PI double staining with the use of flow cytometry analysis (data represent means ± SE).

This Feature Is Available To Subscribers Only